Skip to main content
Cold and flu season Temporada de influenza y resfriados

ALERT: Stay healthy this cold and flu season! Learn more

ALERTA: ¡Mantente sano durante esta temporada de influenza y resfriados! Más información

New Website! ¡Nuevo sitio web!

ALERT: We have made the Texas Children’s Health Plan website even easier to use! Click here to learn more.

ALERTA: ¡Ahora el sitio web de Texas Children’s Health Plan es aún más sencillo de usar! Haz clic aquí para más información.

Enfamil shortage updates Escasez de Enfamil Reguline

ALERT: Shortage of Enfamil products until October 31, 2024. Learn more.

ALERTA: Escasez de productos de Enfamil hasta el 31 de octubre de 2024. Más información.

Change Healthcare Incident Change Healthcare incidente

Non-Risk Based Status for Zynteglo Began July 1, 2023

Date: August 28, 2023

Attention: Physicians

Effective Date: July 1, 2023

Call to action: Texas Children’s Health Plan (TCHP) would like to let you know that effective July 1, 2023, reimbursement for Zynteglo is non-risk. Zynteglo (procedure code J3590) is a gene therapy for treating adult and pediatric clients with beta-thalassemia requiring regular blood cell (RBC) transfusions.

How this impacts providers: Zynteglo is administered in a qualifying treatment center (QTC) for clients that meet prior authorization criteria. QTC is required to send the prescription to the manufacturer-authorized specialty pharmacy, which will process the claim for Zynteglo. Texas Children’s Hospital Medical Center is the only active Qualified Treatment Center for Zynteglo at this time. MCOs will be reimbursed non-risk for Zynteglo when billed through the outpatient drug benefit. To be eligible for reimbursement, medical encounters must contain a Financial Arrangement Code of “20”. The clients’ inpatient hospitalization will be billed under diagnosis-related group (DRG) and is not eligible for non-risk reimbursement.

Refer to the Outpatient Drug Services Handbook Chapter of the Texas Medicaid Provider Procedure Manual for more details on the clinical policy and prior authorization requirements.

Next steps for providers: Prescribers should share this communication with their staff. Provider must make sure to send the Zynteglo prescription to the manufacturer-authorized specialty pharmacy and the pharmacy will process the claim for the drug.

06/13/2024 Update: For information on the current maximum allowable reimbursement for Zynteglo, please review the following Provider Alert: https://www.thecheckup.org/2024/06/12/provider-alert-maximum-allowable-update-for-non-risk-based-drugs-billed-with-unclassified-procedure-codes/

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.

For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.